Latest News

Fluid biomarkers: theory and practice


ACTRIMS Forum 2024

Considerable progress has been made in recent years in determining the place in therapy of fluid biomarkers of multiple sclerosis and other neurological disorders. Among the most studied are neurofilament-light chain (NfL), a marker of neuroaxonal damage, and glial fibrillary acidic protein (GFAP), a marker of astrogliosis. The following summarizes fluid biomarker studies presented at the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum, held February 29 to March 2, 2024, in West Palm Beach, Florida. Read More

Evobrutinib in MS – ACTRIMS Forum update


Merck KGaA announced in December the top-line results of its failed phase III trials of evobrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, but few details were available at that time. Full results have now been presented by Dr. Xavier Montalban, Barcelona, Spain, at the ACTRIMS Forum conference, held February 29-March 2 in West Palm Beach, Florida. Read More